Hello, Fool! | Login | Signup | My Fool
Nov 21, 2008 12:23 PM ET | Feedback | Site Changes | Help
A biopharmaceutical company dedicated to improving and preserving human life by developing innovative pharmaceutical products.
View All Commentary (LJPC)
Recs
zzlangerhans (99.39) Submitted: 7/05/07 2:56 AM : Start Price: $4.45 LJPC Score: 38.64
The clock is ticking on Riquent which will fail this phase III as it did in previous trials. This is a classic example of a company clinging to a single doomed product in order to extend the careers of the board and top management. I expect "shock and disappointment" when the negative interim results are released in 2008.
Report this Post Replies: 1 | Reply | Permalink
Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
zzlangerhans (99.39) Submitted: 10/17/08 1:30 PM
Recs: 0 | Rec This
Riquent and La Jolla will die in 2009, but I don't feel like waiting. If the market pops up by then then I'll be leaving points on the table, but I think we could be looking at a long period of stagnation. I'm picking a nice up day, over 40 points on the red thumb. Point made.
Report this Post Reply
Terms & Conditions
RSS Headlines
Fool UK